Roivant Seeks Edge In Drug Development With $450M Silicon Therapeutics Purchase


Roivant Sciences has announced the acquisition of Silicon Therapeutics for $450 million in Roivant stock. With the purchase, Roivant is seeking to improve its drug development abilities with Silicon’s cutting edge computational physics platform.


Silicon Therapeutics’ platform uses quantum mechanics, molecular dynamics and statistical thermodynamics models to predict binding energies and the conformational behavior of molecules. A failure to solve these issues can often lead to major bottlenecks in the drug development process, holding back breakthroughs.


In a statement, Silicon Therapeutics Chairman Roger Pomerant said, “The combination of Silicon Therapeutics’ integrated approach, platform and highly capable team with Roivant’s technologies and commitment to transforming the pharmaceutical industry represents a new and exciting paradigm in drug discovery and development.”